An Acromegaly open-label multi-center Safety monitoring program for treating patients with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS)

ID Number 14-0032

Principal Investigator(s)
Eliza B Geer

Department(s) or Division(s)
Endocrinology, Diabetes and Bone Disease


The purpose of this study is to find out if the long acting formulation of drug Pasireotide is safe and has beneficial effects in people who have Acromegaly.

Contact Information
Yelena Lalazar
(212) 241-2613

Recruiting Patients: Yes